Product Name Doxycycline
CAS No.: 564-25-0
Catalog No.: CFN90251
Molecular Formula: C22H24N2O8
Molecular Weight: 444.44 g/mol
Purity: >=98%
Type of Compound: Alkaloids
Physical Desc.: Powder
Targets: TNF-α | IL Receptor | PI3K | Akt | NOS
Source: From Gliocladium virens
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Doxycycline, an inhibitor of matrix metalloproteinases, has beneficial effects on sulfur mustard-induced ocular pathologies depend on the injury stage. Doxycycline inhibits B cell, MC and histamine function and attenuates experimental allergic conjunctivitis and systemic anaphylaxis by possible modulating the PI3K/Akt pathway.Doxycycline treatment of microfilaremic dogs gradually reduces numbers of microfilariae and blocks further transmission of heartworms, also has a slow-kill effect on adult heartworms.
Inquire / Order:
Technical Inquiries:
Tel: +86-27-84237783
Fax: +86-27-84254680

1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to:

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • The Catharanthus Genome2022,35-83.
  • Anal Chim Acta.2021, 1180:338874.
  • Analytical Letters.2020, doi 10.1008
  • Int Immunopharmacol.2023, 7:127:111322.
  • Molecules.2021, 26(4):816.
  • Food Funct.2020, 11(2):1322-1333.
  • J Cosmet Dermatol.2022, 21(1):396-402.
  • Chinese Pharmaceutical Journal2023, 58(2):178-187.
  • Biomolecules.2024, 14(4):451.
  • Front Pharmacol.2016, 7:460
  • 2-Anthraquinonecarboxylic acid

    Catalog No: CFN92537
    CAS No: 117-78-2
    Price: $40/20mg

    Catalog No: CFN99157
    CAS No: 478-43-3
    Price: $40/20mg

    Catalog No: CFN93079
    CAS No: 34298-86-7
    Price: $168/20mg

    Catalog No: CFN90145
    CAS No: 13739-02-1
    Price: $30/20mg
    Ophiohayatone C

    Catalog No: CFN92701
    CAS No: 84-33-3
    Price: Inquiry(

    Catalog No: CFN95101
    CAS No: 1401414-53-6
    Price: $338/5mg

    Catalog No: CFN98723
    CAS No: 477-84-9
    Price: Inquiry(
    Carminic acid

    Catalog No: CFN94408
    CAS No: 1260-17-9
    Price: $30/20mg
    Laccaic acid E

    Catalog No: CFN00084
    CAS No: 14597-16-1
    Price: Inquiry(

    Catalog No: CFN90251
    CAS No: 564-25-0
    Price: Inquiry(
    Ann Hematol. 2015 Apr;94(4):575-81.
    Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma.[Pubmed: 25338969]
    Ocular adnexal lymphoma (OAL) has been associated with Chlamydophila psittaci infection, for which Doxycycline has been suggested as a treatment option.
    We conducted this study to evaluate the long-term results of first-line Doxycycline treatment in patients with OAL. Ninety patients with histologically confirmed OAL with marginal zone B cell lymphoma were enrolled. Each patient received one or two cycles of Doxycycline (100 mg bid) for 3 weeks. After a median follow-up period of 40.5 months (8-85), the 5-year progression-free survival (PFS) rate was 60.9 %. All patients were alive at the last follow-up date. Thirty-one patients (34 %) showed local treatment failure without systemic spread. However, PFS rate in these patients was 100 % after salvage chemotherapy and/or radiotherapy. PFS was independently predicted in multivariate analysis by the tumor-node-metastasis (TNM) staging (hazard ratio [HR], 4.35; 95 % confidence interval [CI], 2.03-9.32; P < 0.001) and number of cycles of Doxycycline (HR, 0.31; 95 % CI, 0.14-0.69; P = 0.004). No serious adverse event was reported during Doxycycline therapy.
    In conclusion, first-line Doxycycline therapy was effective and safe. Patients who failed to respond to Doxycycline therapy were successfully salvaged with chemotherapy and/or radiotherapy without compromising long-term outcomes. Patients with T1N0M0 disease could be considered good candidates for first-line Doxycycline.
    Curr Eye Res. 2014 Aug;39(8):803-12.
    The beneficial effects of doxycycline, an inhibitor of matrix metalloproteinases, on sulfur mustard-induced ocular pathologies depend on the injury stage.[Pubmed: 24502433]
    Sulfur mustard (SM) induces acute ocular lesions, including erosions and inflammation that may be followed by delayed injuries expressed by epithelial defects and neovascularization (NV). Based on the matrix metalloproteinases (MMPs) activity, we evaluated the clinical and biochemical effects of topical treatment with Doxycycline, an MMP inhibitor, targeted to the various injury stages.
    Rabbit eyes were exposed to SM vapor. A clinical follow-up was carried out up to 2 months. Tear fluid and cornea samples were collected at different time points for measurements of MMPs activity by zymography. Efficacy of a post-exposure topical Doxycycline (2 mg/ml in phosphate buffer saline, ×4/d), targeted to the different phases of the clinical injury, was evaluated. Elevated MMP-9 and MMP-2 activities were found in all corneas during the acute injury and in vascularized corneas during the delayed pathology. In the tear fluid, high MMP-9 activity and negligible MMP-2 activity were found in all the exposed eyes until after the appearance of the delayed pathology symptoms. Prolonged Doxycycline treatment reduced MMP-9 activity in the tear fluid. During the acute phase, Doxycycline treatment reduced corneal MMP-9 activity and the severity of the injury. Targeting the delayed pathology, Doxycycline was clinically efficient only when treatment began before NV appearance.
    This in vivo study showed the involvement of MMP-9 and MMP-2 during different phases of the SM-induced ocular injury, and the potential of Doxycycline treatment as a post exposure measure for reducing the acute injury and as a preventive therapy for ameliorating the delayed pathology. The tear fluid provided a non-invasive method for continuous follow-up of MMPs activity and revealed additional beneficial aspects of injury and the treatment.
    Biochem Pharmacol. 2014 Oct 1;91(3):359-68.
    Doxycycline exerts multiple anti-allergy effects to attenuate murine allergic conjunctivitis and systemic anaphylaxis.[Pubmed: 25128381]
    Allergic diseases, which affect up to 20-30% of the world population, are still therapeutic challenge for allergists. Tetracyclines, which belong to an antibiotic drug family that possesses a striking variety of non-antibiotic properties, have been successfully applied to a wide range of diseases. However, their roles in allergic conjunctivitis and anaphylaxis and their underlying anti-allergy mechanisms remain elusive.
    Here, we reported that treatment with Doxycycline significantly reduced IgE release from mouse B cells and the degranulation and inflammatory cytokines production of mouse mast cells (MCs) activated by IgE-dependent way. Furthermore, Doxycycline treatment significantly inhibited histamine-induced vascular hyperpermeability in vitro. Mechanistically, the Doxycycline-mediated inhibition of B cells, MCs and histamine may occur via modulation of the PI3K/Akt pathway. In vivo, our results demonstrated that treatment with Doxycycline significantly attenuated clinical symptoms of mouse models of experimental allergic conjunctivitis (EAC) with a significant decrease in inflammatory cell frequency, IgE production, histamine release, and a decrease in TNF-α and IL-4 production. Using mouse models of MCs-dependent passive systemic anaphylaxis (PSA), we further confirmed anti-allergy effects of Doxycycline and Doxycycline-mediated inhibitory effects on MCs. Furthermore, our results showed that Doxycycline significantly attenuate histamine-induced systemic anaphylaxis-like reaction (HISA) with a significantly downregulation of PI3K/Akt/eNOS/VE-cadherin pathway. The Doxycycline-mediated anti-allergy effects during EAC, PSA and HISA were abrogated when an Akt activator, SC79, was administered.
    These findings suggest that Doxycycline inhibits B cell, MC and histamine function and attenuates experimental allergic conjunctivitis and systemic anaphylaxis by possible modulating the PI3K/Akt pathway.
    Vet Parasitol. 2014 Nov 15;206(1-2):5-13.
    Effects of doxycycline on heartworm embryogenesis, transmission, circulating microfilaria, and adult worms in microfilaremic dogs.[Pubmed: 25458121]
    Tetracycline treatment of animals or humans infected with filariae that harbor Wolbachia endosymbionts blocks further embryogenesis, and existing microfilariae gradually die. This treatment also kills developing larvae and has a slow-kill effect on adult filariae, all presumably due to elimination of the Wolbachia. Also, Dirofilaria immitis microfilariae in blood collected from dogs up to 25 days after the last dose of Doxycycline developed to infective L3 that were normal in appearance and motility in mosquitoes but did not continue to develop or migrate normally after subcutaneous (SC) injection into dogs. The present study was designed to determine whether heartworm microfilariae collected at later times after treatment would regain the ability to continue normal development in a dog. The study also was expected to yield valuable data on the effects of treatment on microfilariae and antigen levels and adult worms.
    The study was conducted in 16 dogs as two separate replicates at different times. A total of five dogs (two in Replicate A and three in Replicate B) infected either by SC injection of L3 or intravenous transplantation of adult heartworms were given Doxycycline orally at 10mg/kg twice daily for 30 days, with three untreated controls. Microfilarial counts in the five treated dogs gradually declined during the 12-13 months after treatment initiation. Two dogs were amicrofilaremic before necropsy and three had 13 or fewer microfilariae/ml. Only one treated dog was negative for heartworm antigen before necropsy. Overall, treated dogs generally had fewer live adult heartworms than controls, and most of their live worms were moribund. All three control dogs remained positive for microfilariae and antigen and had many live worms. L3 from mosquitoes fed on blood collected 73-77 or 161-164 days after initiation of Doxycycline treatments were injected SC into five dogs. None of the dogs injected with L3 from mosquitoes fed on blood from Doxycycline-treated dogs were ever positive for microfilariae or antigen, and none had worms at necropsy; three control dogs were positive for microfilariae and antigen and had many live worms.
    These data indicate that Doxycycline treatment of microfilaremic dogs gradually reduces numbers of microfilariae and blocks further transmission of heartworms. This latter effect should be highly effective in reducing the rate of selection of heartworms with genes that confer resistance to macrocyclic lactone preventives and microfilaricides. The data also suggest that Doxycycline has a slow-kill effect on adult heartworms.
    Lucidumol A

    Catalog No: CFN95059
    CAS No: 217476-73-8
    Price: $318/5mg
    6''-O-Acetylsaikosaponin D

    Catalog No: CFN95090
    CAS No: 64340-45-0
    Price: $288/5mg

    Catalog No: CFN95094
    CAS No: 53681-67-7
    Price: $288/10mg
    New compound 4

    Catalog No: CFN95185
    CAS No: N/A
    Price: $368/5mg
    Methylgomisin O

    Catalog No: CFN95236
    CAS No: 1276654-07-9
    Price: $318/5mg
    Polygalacin D2

    Catalog No: CFN95241
    CAS No: 66663-92-1
    Price: $413/5mg
    Foliachinenoside C

    Catalog No: CFN95361
    CAS No: 1041180-87-3
    Price: $368/5mg
    Crepidiaside B

    Catalog No: CFN95432
    CAS No: 101921-35-1
    Price: $318/10mg
    3beta-(alpha-L-Arabinopyranosyloxy)urs-12,18-dien-28-oic acid beta-D-glucopyranosyl ester

    Catalog No: CFN95459
    CAS No: 435269-07-1
    Price: $318/20mg
    Oxytroflavoside F

    Catalog No: CFN95489
    CAS No: 1391144-85-6
    Price: $318/5mg